A recent study in prostate cancer cell lines showed that an HER2/ERBB3 signalling pathway protected the AR from degradation by the ubiquitin–proteasome pathway and enhanced AR transcriptional activity at low androgen concentrations (Mellinghoff et al, 2004). Here, AR is linked to prostate cancer.